Advanced search
1 file | 774.94 KB Add to list

Early high antibody titre convalescent plasma for hospitalised COVID-19 patients : DAWn-plasma

Author
Organization
Abstract
Background Several randomised clinical trials have studied convalescent plasma (CP) for COVID-19 using different protocols, with different SARS-CoV-2 neutralising-antibody-titres, at different time-points and severities of illness. Methods In the prospective multicentre DAWN-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising-antibody-titres (NT50) ≥1/320 was the product of choice for the study. Results Between May 2nd, 2020 and January 26th, 2021, 320 patients were randomised to convalescent plasma and 163 patients to the control group according to a 2:1 allocation scheme. A median volume of 884 mL convalescent plasma (IQR 806–906 mL) was administered, and 80.68% of the units came from donors with neutralising-antibody-titres (NT50) ≥1/320. Median time from onset of symptoms to randomisation was 7 days. The proportion of patients alive and free of mechanical ventilation on Day 15 was not different between both groups (convalescent plasma: 83.74% (n=267) versus control: 84.05% (n=137) – Odds ratio 0.99 (0.59–1.66) – p-value=0.9772). The intervention did not change the natural course of antibody titres. The number of serious or severe adverse events was similar in both study arms, and transfusion-related side effects were reported in 19/320 patients in the intervention group (5.94%). Conclusions Transfusion of 4 units of convalescent plasma with high neutralising-antibody-titres early in hospitalised COVID-19 patients did not result in a significant improvement of the clinical status, or a reduced mortality.
Keywords
Pulmonary and Respiratory Medicine

Downloads

  • published.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 774.94 KB

Citation

Please use this url to cite or link to this publication:

MLA
Devos, Timothy, et al. “Early High Antibody Titre Convalescent Plasma for Hospitalised COVID-19 Patients : DAWn-Plasma.” EUROPEAN RESPIRATORY JOURNAL, vol. 59, 2022, doi:10.1183/13993003.01724-2021.
APA
Devos, T., Van Thillo, Q., Compernolle, V., Najdovski, T., Romano, M., Dauby, N., … DAWn-plasma investigators, [ missing ]. (2022). Early high antibody titre convalescent plasma for hospitalised COVID-19 patients : DAWn-plasma. EUROPEAN RESPIRATORY JOURNAL, 59. https://doi.org/10.1183/13993003.01724-2021
Chicago author-date
Devos, Timothy, Quentin Van Thillo, Veerle Compernolle, Tomé Najdovski, Marta Romano, Nicolas Dauby, Laurent Jadot, et al. 2022. “Early High Antibody Titre Convalescent Plasma for Hospitalised COVID-19 Patients : DAWn-Plasma.” EUROPEAN RESPIRATORY JOURNAL 59. https://doi.org/10.1183/13993003.01724-2021.
Chicago author-date (all authors)
Devos, Timothy, Quentin Van Thillo, Veerle Compernolle, Tomé Najdovski, Marta Romano, Nicolas Dauby, Laurent Jadot, Mathias Leys, Evelyne Maillart, Sarah Loof, Lucie Seyler, Martial Moonen, Michel Moutschen, Niels Van Regenmortel, Kevin K. Ariën, Cyril Barbezange, Albrecht Betrains, Mutien Garigliany, Matthias M. Engelen, Iwein Gyselinck, Piet Maes, Alexander Schauwvlieghe, Laurens Liesenborghs, Ann Belmans, Peter Verhamme, Geert Meyfroidt, and [ missing ] DAWn-plasma investigators. 2022. “Early High Antibody Titre Convalescent Plasma for Hospitalised COVID-19 Patients : DAWn-Plasma.” EUROPEAN RESPIRATORY JOURNAL 59. doi:10.1183/13993003.01724-2021.
Vancouver
1.
Devos T, Van Thillo Q, Compernolle V, Najdovski T, Romano M, Dauby N, et al. Early high antibody titre convalescent plasma for hospitalised COVID-19 patients : DAWn-plasma. EUROPEAN RESPIRATORY JOURNAL. 2022;59.
IEEE
[1]
T. Devos et al., “Early high antibody titre convalescent plasma for hospitalised COVID-19 patients : DAWn-plasma,” EUROPEAN RESPIRATORY JOURNAL, vol. 59, 2022.
@article{8746255,
  abstract     = {{Background
Several randomised clinical trials have studied convalescent plasma (CP) for COVID-19 using different protocols, with different SARS-CoV-2 neutralising-antibody-titres, at different time-points and severities of illness.

Methods
In the prospective multicentre DAWN-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising-antibody-titres (NT50) ≥1/320 was the product of choice for the study.

Results
Between May 2nd, 2020 and January 26th, 2021, 320 patients were randomised to convalescent plasma and 163 patients to the control group according to a 2:1 allocation scheme. A median volume of 884 mL convalescent plasma (IQR 806–906 mL) was administered, and 80.68% of the units came from donors with neutralising-antibody-titres (NT50) ≥1/320. Median time from onset of symptoms to randomisation was 7 days. The proportion of patients alive and free of mechanical ventilation on Day 15 was not different between both groups (convalescent plasma: 83.74% (n=267) versus control: 84.05% (n=137) – Odds ratio 0.99 (0.59–1.66) – p-value=0.9772). The intervention did not change the natural course of antibody titres. The number of serious or severe adverse events was similar in both study arms, and transfusion-related side effects were reported in 19/320 patients in the intervention group (5.94%).

Conclusions
Transfusion of 4 units of convalescent plasma with high neutralising-antibody-titres early in hospitalised COVID-19 patients did not result in a significant improvement of the clinical status, or a reduced mortality.}},
  articleno    = {{2101724}},
  author       = {{Devos, Timothy and Van Thillo, Quentin and Compernolle, Veerle and Najdovski, Tomé and Romano, Marta and Dauby, Nicolas and Jadot, Laurent and Leys, Mathias and Maillart, Evelyne and Loof, Sarah and Seyler, Lucie and Moonen, Martial and Moutschen, Michel and Van Regenmortel, Niels and Ariën, Kevin K. and Barbezange, Cyril and Betrains, Albrecht and Garigliany, Mutien and Engelen, Matthias M. and Gyselinck, Iwein and Maes, Piet and Schauwvlieghe, Alexander and Liesenborghs, Laurens and Belmans, Ann and Verhamme, Peter and Meyfroidt, Geert and DAWn-plasma investigators, [ missing ]}},
  issn         = {{0903-1936}},
  journal      = {{EUROPEAN RESPIRATORY JOURNAL}},
  keywords     = {{Pulmonary and Respiratory Medicine}},
  language     = {{eng}},
  pages        = {{12}},
  title        = {{Early high antibody titre convalescent plasma for hospitalised COVID-19 patients : DAWn-plasma}},
  url          = {{http://dx.doi.org/10.1183/13993003.01724-2021}},
  volume       = {{59}},
  year         = {{2022}},
}

Altmetric
View in Altmetric